Update on Immunotherapy in metastatic Bladder Cancer

Ravindran Kanesvaran Consultant Medical Oncologist National Cancer Centre Singapore President, Singapore Society of Oncology (SSO)





Members of the SingHealth Group Changi General Hospital • KK Women's and Children's Hospital • Singapore General Hospital National Cancer Centre Singapore • National Dental Centre • National Heart Centre • National Neuroscience Institute • Singapore National Eye Centre SingHealth Polyclinics

Disclosures

- Speaker Bureau: Pfizer, J&J, Sanofi, Novartis, MSD
- Advisory Board/ Consultant: GSK, Novartis, Bayer, J&J, Mundipharma, Astellas, MSD, BMS
- Research support: Sanofi, J&J, Astellas







Outline

• Current standard

• Immunotherapy in mBC

• Clinical Trials

• Summary (Come Monday)







Current Standard

NCCN National Comprehensive Cancer Network[®]

NCCN Guidelines Version 3.2017 Bladder Cancer

NCCN Guidelines Index Table of Contents Discussion

PRINCIPLES OF SYSTEMIC THERAPY

First-line chemotherapy for locally advanced or metastatic disease

	Standard regimens	Alternate regimens for select patients
Cisplatin eligible	 Gemcitabine and cisplatin⁴ (category 1) DDMVAC with growth factor support (category 1)^{2,8} 	
Cisplatin ineligible	 Gemcitabine and carboplatin¹¹ Atezolizumab¹² 	 Gemcitabine¹³ Gemcitabine and paclitaxel¹⁴ Ifosfamide, doxorubicin, and gemcitabine¹⁵ (for patients with good kidney function and good PS)

- The presence of both visceral metastases and ECOG performance score ≥2 strongly predict poor outcome with chemotherapy. Patients
 without these adverse prognostic factors have the greatest benefit from chemotherapy.
- For most patients, the risks of adding paclitaxel to gemcitabine and cisplatin outweigh the limited benefit seen in the randomized trial.¹⁶
- A substantial proportion of patients cannot receive cisplatin-based chemotherapy due to renal impairment or other comorbidities.
 Participation in clinical trials of new or more tolerable therapy is recommended.

Subsequent systemic therapy for locally advanced or metastatic disease

Participation in clinical trials of new agents is recommended.

Standard regimens	Alternate regimens for select patients
 Pembrolizumab (category 1)¹⁷ 	Nab-paclitaxel ²³
 Atezolizumab¹⁸ 	 Ifosfamide²⁴
 Nivolumab¹⁹ 	Methotrexate
• Durvalumab ²⁰	 Ifosfamide, doxorubicin, and gemcitabine¹⁵
 Paclitaxel or docetaxel²¹ 	 Gemcitabine and paclitaxel¹⁴
 Gemcitabine¹³ 	 Gemcitabine and cisplatin⁴
Pemetrexed ²²	DDMVAC ²

Continued on <u>BL-G 3 of 4</u>

References on BL-G 4 of 4







Outline

• Current standard

• Immunotherapy in mBC

• Clinical Trials

• Summary (Come Monday)







Outline

- Current standard
- Immunotherapy in mBC
- Clinical Trials
- Summary (Come Monday)





IMvigor 210, a Phase II trial of Atezolizumab (MPDL3280A) in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma (mUC)

Jean Hoffman-Censits,¹ Petros Grivas,² Michiel S. van der Heijden,³ Robert Dreicer,⁴ Yohann Loriot,⁵ Margitta Retz,⁶ Nicholas J. Vogelzang,⁷ Jose Luis Perez-Gracia,⁸ Arash Rezazadeh Kalebasty,⁹ Sergio Bracarda,¹⁰ Evan Y. Yu,¹¹ Christopher Hoimes,¹² Joaquim Bellmunt,¹³ David I. Quinn,¹⁴ Daniel P. Petrylak,¹⁵ Syed A. Hussain,¹⁶ Na Cui,¹⁷ Sanjeev Mariathasan,¹⁷ Oyewale Abidoye,¹⁷ Jonathan E. Rosenberg¹⁸

¹Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, PA, USA; ²Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA; ³Netherlands Cancer Institute, Amsterdam, Netherlands; ⁴Division of Hematology/Oncology, University of Virginia, Charlottesville VA USA; ⁵Gustave Roussy, Villejuif, France; ⁶Urologische Klinik und Poliklinik, Technische Universität München, Munich, Germany; ⁷US Oncology Research/Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA; ⁸Clinica Universidad de Navarra, Pamplona, Spain; ⁹Norton Cancer Institute, Louisville, KY, USA; ¹⁰USL8 Ospedale San Donato, Arezzo, Italy; ¹¹University of Washington and Seattle Cancer Care Alliance, Seattle, WA, USA; ¹²Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA; ¹³Bladder Cancer Center, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA; ¹⁴USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA; ¹⁵Yale Cancer Center, New Haven, CT, USA; ¹⁶University of Liverpool, Clatterbridge Cancer Center, Liverpool, UK; ¹⁷Genentech, Inc, South San Francisco, CA, USA; ¹⁸Memorial Sloan Kettering Cancer Center, New York, NY, USA.

PRESENTED AT: **2016 Genitourinary Cancers Symposium** Slides are the property of the author. Permission required for reuse. Hoffman-Censits et al. IMvigor 210, 2016

Presented By Jean Hoffman-Censits at Genitourinary Cancers Symposium 2016








IMvigor 210: PD-L1 Immune Cell Expression (IHC)

PD-L1 expression on IC was evaluated with the VENTANA SP142 IHC assay based on 3 scoring levels: IC2/3 (≥ 5%), IC1 (≥ 1 but < 5%), IC0 (< 1%)¹



Images at 10x magnification. **Reference: 1.** Rosenberg JE, et al. ECC 2015 [abstract 21LBA].

PRESENTED AT: **2016 Genitourinary Cancers Symposium** *Slides are the property of the author. Permission required for reuse.* Hoffman-Censits et al. IMvigor 210, 2016

Presented By Jean Hoffman-Censits at Genitourinary Cancers Symposium 2016







IMvigor 210: Responses to Atezolizumab

	IC2/3	IC1/2/3	All	IC1	IC0
	(n = 100)	(n = 207)	(N = 310)	(n = 107)	(n = 103)
ORR (95% CI) per confirmed	26%	18%	15%	10%	8%
IRF RECIST v1.1	(18, 36)	(13, 24)	(11, 19)	(5, 18)	(3, 15)
ORR (95% CI) per investigator	27%	22%	19%	17%	13%
mRECIST	(19, 37)	(16, 28)	(15, 24)	(10, 25)	(7, 21)
Complete response (CR) per confirmed IRF RECIST v1.1	11%	6%	5%	2%	2%

 Higher ORR was associated with higher PD-L1 IHC status, but responses were seen in all PD-L1 subgroups

Objective response evaluable population: all treated patients had measurable disease at baseline per investigator-assessed RECIST v1.1. Data cutoff: September 14, 2015.

PRESENTED AT: **2016 Genitourinary Cancers Symposium** *Slides are the property of the author. Permission required for reuse.* Hoffman-Censits et al. IMvigor 210, 2016

Presented By Jean Hoffman-Censits at Genitourinary Cancers Symposium 2016







IMvigor 210: Phase II Atezolizumab in mUC Conclusions

- This primary analysis of cohort 2 demonstrated that atezolizumab has the potential to change the standard of care in mUC:
 - ORRs represented clinical improvements over a historical 10% ORR
 - Higher PD-L1 IC status was associated with higher ORR, but low expression did not preclude response
 - mDOR was not reached in any pre-defined PD-L1 or poor prognostic subgroup
 - mOS was 11.4 months in IC2/3 patients and 6.7 months in IC0/1 patients
 - Atezolizumab was well tolerated with a low rate of treatment-related Grade 3-4 toxicities and no treatment-related Grade 5 AEs
- Ongoing studies in the atezolizumab UC clinical development program include:
 - 2 randomized Ph III studies in adjuvant MIBC (NCT02450331) and mUC (NCT02302807)
 - An expanded access study (NCT02589717) for patients with mUC who experience disease progression post platinum chemotherapy

IMvigor 210: Outline

• Current standard

• Immunotherapy in mBC

• Clinical Trials

• Summary (Come Monday)







Accelerated approval Atezolizumab

- Azetolizumab (Tecentriq) approved to treat patients with urothelial carcinoma whose disease has worsened during or following platinum-containing chemotherapy, or within 12 months of receiving platinum containing chemotherapy, either before or after surgical treatment.
- PII single arm (n=310) with locally advanced or metastatic urothelial carcinoma. ORR 15%. ORR PD-L1+ 29%, PD-L1- 10%
- Approved with Ventana PD-L1 assay to detect PD-L1 IC staining





Accelerated approval for Nivolumab

News & Perspective > Medscape Medical News > FDA Approvals

FDA Approves Nivolumab for Bladder Cancer

Nick Mulcahy DISCLOSURES | February 02, 2017

The US Food and Drug Administration (FDA) today approved nivolumab (*Opdivo*, Bristol-Myers Squibb) for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed during a period of up to 1 year after first-line platinum-containing chemotherapy.

The accelerated approval makes nivolumab, which is a programmed cell death receptor–1 inhibitor, the second immunotherapy approved in this setting in the past year. The agency approved atezolizumab (*Tecentriq*, Genentech/Roche), which acts as a programmed cell death ligand–1 inhibitor, in May 2016.

Both nivolumab and atezolizumab received an accelerated approval on the basis of response rates; data on other outcomes, including survival, are awaited.







Accelerated approval for Durvalumab

FDA Approves Imfinzi (Durvalumab) for Bladder Cancer

💾 May 2, 2017

The US Food and Drug Administration (FDA) has approved the immunotherapy drug Imfinzi (durvalumab) to treat people with advanced urothelial carcinoma, the most common type of bladder cancer. The new drug is approved for use in people who have already had chemotherapy.

Imfinzi is part of a new class of immunotherapy drugs called checkpoint inhibitors. It's the third checkpoint inhibitor to be approved for bladder cancer. This drug, given as an infusion, targets the PD-L1 protein, which some cancer cells use to evade the immune system. By blocking PD-L1, it helps immune cells recognize and attack cancer cells.

The FDA also approved a test to check for levels of the PD-L1 protein.







Accelerated approval for Avelumab

News & Perspective > Medscape Medical News > FDA Approvals

Avelumab: Another Immunotherapy for Bladder Cancer

Zosia Chustecka May 09, 2017

Another immunotherapy has been approved for use in urothelial cancer, the most common type of bladder cancer, in the United States.

Avelumab (*Bavencio*, EMD Serono INc), which is a programmed cell death ligand–1 (PD L1) inhibitor, has been approved for second-line use in patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Avelumab was recently approved for the first time worldwide for use in the treatment of Merkel cell carcinoma, a rare and aggressive type of skin cancer.

The new drug joins three similar immunotherapies already approved for similar indications, and experts have said that immunotherapy is already "altering the landscape" for the treatment of bladder cancer.







Is it really making a difference?



ACCELERATED APPROVAL PROGRAM









Was the accelerated approval too early?

Atezolizumab Falls Short in Phase III Bladder Cancer Trial

Jason M. Broderick <u>@jasoncology</u> Published Online: Wednesday, May 10, 2017





Sandra Horning, MD

Atezolizumab (Tecentriq) missed the phase III IMvigor211 trial's primary endpoint of improving overall survival (OS) in the second-line setting for patients with locally advanced or metastatic urothelial carcinoma (mUC), according to Genentech, the manufacturer of the PD-L1 inhibitor.

The IMvigor211 study was intended to confirm the findings of the phase II IMvigor210 study, on which the FDA based its May 2016 accelerated approval of atezolizumab as a treatment for patients with locally





Keynote 045



The NEW ENGLAND JOURNAL of MEDICINE

HOME	ARTICLES & MULTIMEDIA *	ISSUES *	SPECIALTIES & TOPICS *	FOR AUTHORS *	CME >
------	-------------------------	----------	------------------------	---------------	-------

ORIGINAL ARTICLE


Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Joaquim Bellmunt, M.D., Ph.D., Ronald de Wit, M.D., Ph.D., David J. Vaughn, M.D., Yves Fradet, M.D., Jae-Lyun Lee, M.D., Ph.D., Lawrence Fong, M.D., Nicholas J. Vogelzang, M.D., Miguel A. Climent, M.D., Daniel P. Petrylak, M.D., Toni K. Choueiri, M.D., Andrea Necchi, M.D., Winald Gerritsen, M.D., Ph.D., Howard Gurney, M.D., David I. Quinn, M.D., Ph.D., Stéphane Culine, M.D., Ph.D., Cora N. Sternberg, M.D., Yabing Mai, Ph.D., Christian H. Poehlein, M.D., Rodolfo F. Perini, M.D., and Dean F. Bajorin, M.D., for the KEYNOTE-045 Investigators[®] N Engl J Med 2017; 376:1015-1026 [March 16, 2017] DOI: 10.1056/NEJMoa1613683





KEYNOTE-045: Study Design



Key End Points

Primary: OS and PFS in total and PD-L1 CPS ≥10% populations Secondary: OR and DOR in total and PD-L1 CPS ≥10% populations; safety in total population

CPS = combined positive score; DOR = duration of response; ECOG = Eastern Cooperative Oncology Group; IV = intravenous; OS = overall survival; PD = progressive disease; PD-L1 = programmed death ligand 1; PFS = progression-free survival; PS = performance status; Q3W – every 3 weeks; R = randomization. 1. Bellmunt J, et al. *N Engl J Med.* 2017; February 17 [Epub ahead of print].

MSD Oncology





KEYNOTE-045: Baseline Characteristics

Characteristic	Pembrolizumab Group (N=270)	Chemotherapy Group (N=272)
Age — yr		
Median	67	65
Range	29–88	26–84
Male sex — no. (%)	200 (74.1)	202 (74.3)
ECOG performance-status score — no. (%)†		
0	119 (44.1)	106 (39.0)
1	143 (53.0)	158 (58.1)
2	2 (0.7)	4 (1.5)
Missing data	6 (2.2)	4 (1.5)
Current or former smoker — no./total no. (%)	165/269 (61.3)	186/269 (69.1)
Pure transitional-cell features in histologic testing — no./total no. (%)	186/270 (68.9)	197/270 (73.0)
Tumor PD-L1 combined positive score ≥10% — no./total no. (%)‡	74/260 (28.5)	90/266 (33.8)
Site of primary tumor in bladder or urethra — no./total no. (%)	232/270 (85.9)	234/271 (86.3)
Visceral disease — no./total no. (%)	240/269 (89.2)	233/271 (86.0)
Liver metastases — no./total no. (%)	91/270 (33.7)	95/271 (35.1)
Hemoglobin concentration <10 g/dl — no./total no. (%)	43/262 (16.4)	44/267 (16.5)
No. of risk factors — no. (%)∬		
0	54 (20.0)	44 (16.2)
1	96 (35.6)	97 (35.7)
2	66 (24.4)	80 (29.4)
3 or 4	45 (16.7)	45 (16.5)
Missing data	9 (3.3)	6 (2.2)
Completion or discontinuation of most recent therapy <3 mo previously — no./total no. (%)	103/269 (38.3)	104/271 (38.4)

[†] ECOG PS scores range from 0 to 5, with 0 indicating no symptoms and higher scores indicating greater disability.

⁺ PD-L1 CPS: the percentage of tumor and infiltrating immune cells with PD-L1 expression out of the total number of tumor cells.

[§] Risk factors include the Bellmunt risk factors: ECOG PS score >0; hemoglobin concentration <10 g/dL; presence of liver metastases,² plus time since the completion/discontinuation of previous therapy <3 mo.³

CPS = combined positive score; ECOG = Eastern Cooperative Oncology Group; PD-L1 = programmed death ligand 1; PS = performance status.

1. Bellmunt J, et al. N Engl J Med. 2017; February 17 [Epub ahead of print]; 2. Bellmunt J, et al. J Clin Oncol. 2010;28:1850-1855; 3. Sonpavde G, et al. Eur Urol. 2013;63:717-723.







KEYNOTE-045: Baseline Characteristics (contd.)


	Pembrolizumab Group	Chemotherapy Group	
	(N=270)	(N=272)	
Setting of most recent prior therapy,	.‡‡ no. (%)		
Neoadjuvant or adjuvant	31 (11.5)	53 (19.5)	
First line	183 (67.8)	157 (57.7)	
Second line	55 (20.4)	60 (22.1)	
Time since completion or discontinu	lation of most recent prior therap	py,§§ no. (%)	
<3 months	103 (38.1)	104 (38.2)	
≥3 months	166 (61.5)	167 (61.4)	
Prior platinum,§§ no. (%)			
Cisplatin	198 (73.3)	213 (78.3)	
Carboplatin	70 (25.9)	56 (20.6)	
Oxaliplatin or nedaplatin	1 (0.4)	2 (0.7)	
Prior cystectomy or	61 (22.6)	51 (18.8)	
nephroureterectomy, no. (%)			
Prior Bacillus Calmette–Guérin	32 (11.9)	22 (8.1)	
therapy, no. (%)			

1. Bellmunt J, et al. N Engl J Med. 2017; February 17 [Epub ahead of print].





KEYNOTE-045: Overall Survival




CI = confidence interval; CPS = combined positive score.

1. Bellmunt J, et al. N Engl J Med. 2017; February 17 [Epub ahead of print].





KEYNOTE-045: Progression-Free Survival



CI = confidence interval.


1. Bellmunt J, et al. N Engl J Med. 2017; February 17 [Epub ahead of print].

MSD Oncology





KEYNOTE-045: Duration of Response



1. Bellmunt J, et al. N Engl J Med. 2017; February 17 [Epub ahead of print].







KEYNOTE-045: Overall Survival in Key Subgroups

Subgroup	No. of Deaths/ No. of Patients	Hazard Ratio (95% CI)	
Overall	334/542	0.73 (0.59	-0.91)
Age			
<65 yr	149/230	0.75 (0.53	-1.05)
≥65 yr	185/312	0.76 (0.56	-1.02)
Sex			
Male	246/402	0.73 (0.56	-0.94)
Female	88/140	0.78 (0.49	-1.24)
ECOG performance-status score			
0 or 1	323/526	0.74 (0.59	-0.92)
2	5/6	0.43 (0.04	-4.20)
Smoking status			
Current	43/67	0.32 (0.15	-0.68)
Former	170/284	0.71 (0.52	-0.97)
Never	118/187	1.06 (0.72	-1.55)
Histologic type			
Transitional cell	240/383	0.80 (0.62	-1.04)
Mixed	93/155	0.58 (0.37	-
Tumor PD-L1 combined positive sco			
<1%	184/298	0.89 (0.66	-1.20)
≥1%	142/230	0.61 (0.43	-0.86)
Tumor PD-L1 combined positive sco			
<10%	222/362	0.80 (0.61	-1.05)
≥10%	104/164	0.57 (0.37	-0.88)
Location of primary tumor			
Upper tract	48/75	0.53 (0.28	-1.01)
Lower tract	286/466	0.77 (0.60	-0.97)
Location of metastases			
Lymph node only	22/67	0.46 (0.18	-1.21)
Visceral disease	312/473	0.75 (0.60	-0.95)
Liver metastases	-		
Yes	145/186	0.85 (0.61	-1.20)
No	189/355	0.67 (0.50	
	0.	1.0 5.0 Pembrolizumab Better Chemotherapy Better	

CI = confidence interval; ECOG = Eastern Cooperative Oncology Group; PD-L1 = programmed death ligand 1.

1. Bellmunt J, et al. N Engl J Med. 2017; February 17 [Epub ahead of print].

MSD Oncology





KEYNOTE-045: Exposure, AE Summary, and Treatment-Related AEs With Incidence ≥10%1a

Event		umab Group = 266)		erapy Group = 255)
	Any Grade	Grade 3, 4, or 5	Any Grade	Grade 3, 4, or 5
		number of pa	atients (percent)	
Treatment-related event†				
Any event	162 (60.9)	40 (15.0)	230 (90.2)	126 (49.4)
Event leading to discontinuation of treatment	15 (5.6)	12 (4.5)	28 (11.0)	16 (6.3)
Event leading to death	4 (1.5)	4 (1.5)	4 (1.6)	4 (1.6)
Event occurring in ≥10% of patients in either group‡				
Pruritus	52 (19.5)	0	7 (2.7)	1 (0.4)
Fatigue	37 (13.9)	3 (1.1)	71 (27.8)	11 (4.3)
Nausea	29 (10.9)	1 (0.4)	62 (24.3)	4 (1.6)
Diarrhea	24 (9.0)	3 (1.1)	33 (12.9)	2 (0.8)
Decreased appetite	23 (8.6)	0	41 (16.1)	3 (1.2)
Asthenia	15 (5.6)	1 (0.4)	36 (14.1)	7 (2.7)
Anemia	9 (3.4)	2 (0.8)	63 (24.7)	20 (7.8)
Constipation	6 (2.3)	0	52 (20.4)	8 (3.1)
Peripheral sensory neuropathy	2 (0.8)	0	28 (11.0)	5 (2.0)
Neutrophil count decreased	1 (0.4)	1 (0.4)	36 (14.1)	31 (12.2)
Peripheral neuropathy	1 (0.4)	0	27 (10.6)	2 (0.8)
Neutropenia	0	0	39 (15.3)	34 (13.3)
Alopecia	0	0	96 (37.6)	2 (0.8)

AE = adverse event.

1. Bellmunt J, et al. N Engl J Med. 2017; February 17 [Epub ahead of print].







KEYNOTE-045: Safety Events of Interest

Event		imab Group 266)		erapy Group =255)
	Any Grade	Grade 3, 4, or 5	Any Grade	Grade 3, 4, or 5
		number of p	patients (percent)	
Event of interest∬				
Any event	45 (16.9)	12 (4.5)	19 (7.5)	4 (1.6)
Hypothyroidism	17 (6.4)	0	3 (1.2)	0
Hyperthyroidism	10 (3.8)	0	1 (0.4)	0
Pneumonitis	11 (4.1)	6 (2.3)	1 (0.4)	0
Colitis	6 (2.3)	3 (1.1)	1 (0.4)	0
Infusion reaction	2 (0.8)	0	10 (3.9)	0
Nephritis	2 (0.8)	2 (0.8)	0	0
Severe skin reaction	2 (0.8)	1 (0.4)	3 (1.2)	3 (1.2)
Thyroiditis	2 (0.8)	0	0	0
Adrenal insufficiency	1 (0.4)	1 (0.4)	0	0
Myositis	0	0	1 (0.4)	1 (0.4)

AE = adverse event.

1. Bellmunt J, et al. N Engl J Med. 2017; February 17 [Epub ahead of print].

MSD Oncology





KEYNOTE-045: Summary

- Pembrolizumab significantly improved OS over chemotherapy in patients with advanced urothelial carcinoma following first-line platinum-based therapy
 - HR 0.73, P=0.0022
 - OS benefit observed in all PD-L1 populations
- No significant difference in PFS between pembrolizumab and chemotherapy (P=0.42)
- ORR significantly higher and responses more durable with pembrolizumab
 - ORR 21.1% with pembrolizumab vs 11.4% with chemotherapy (P=0.001)
- Lower incidence of treatment-related AEs of any grade (60.9% vs 90.2%) and grade 3-5 severity (15.0% vs 49.4%) with pembrolizumab



AE = adverse event; Hr = hazard ratio; OS = overall survival; PD-L1 = programmed death ligand 1.

^{1.} Bellmunt J, et al. N Engl J Med. 2017; February 17 [Epub ahead of print].

KEYNOTE-045: Conclusions

- Pembrolizumab demonstrated OS improvement compared with chemotherapy in patients with advanced urothelial carcinoma after failure of platinum-based therapy
- Pembrolizumab benefit is observed regardless of PD-L1 expression

OS = overall survival; PD-L1 = programmed death ligand 1.

1. Bellmunt J, et al. N Engl J Med. 2017; February 17 [Epub ahead of print].





KEYNOTE-052

Presented at ASCO GU 2017, Poster 284







Baseline Characteristics & Disease Characteristics (N=370)¹

- Of 541 patients screened, 370 were enrolled and received ≥1 dose of pembrolizumab
 - 307 patients were enrolled for ≥4 months before the data cutoff, and thus had the opportunity for at least 2 postbaseline scans
- Overall, patients were representative of a cisplatin-ineligible population

Characteristic, n (%)	Total Population	
Age, median (range), years	74 (34-94)	
≥80 years	107 (29)	
Male	286 (77)	
ECOG performance status [†]	· · · · · · · · · · · · · · · · · · ·	
0	80 (22)	
1	133 (36)	
2	156 (42)	
Primary tumor location [‡]		
Upper tract	69 (19)	
Lower tract	300 (81)	
Metastases location§		
Lymph node only	51 (14)	
Visceral disease	315 (85)	
Liver metastases	78 (21)	
Previous adjuvant/neoadjuvant platinum-based chemotherapy	36 (10)	
Reasons for cisplatin ineligibility	· · · · · · · · · · · · · · · · · · ·	
ECOG performance status 2	120 (32)	
Renal dysfunction ⁺⁺	182 (49)	
ECOG performance status 2 and renal dysfunction	35 (10)	
Other reasons ^{‡‡}	33 (9)	

[†]One patient had an ECOG performance status of 3. [‡]Primary tumor location unknown for 1 patient. [§] Metastases location not reported for 4 patients. ^{II}Adjuvant platinum-based chemotherapy following radical cystectomy or neoadjuvant platinum-based chemotherapy with recurrence >12 months from completion of therapy was allowed. ^{††}Renal dysfunction defined as creatinine clearance <60 mL/min. ^{‡‡}Other reasons include NYHA Class III heart failure, Grade ≥2 peripheral neuropathy, and Grade ≥2 hearing loss.

ECOG = Eastern Cooperative Oncology Group; NYHA = New York Heart Association.

1. Balar A et al. Presented at: 2017 Genitourinary Cancers Symposium; Feb 16-18, 2017; Orlando, FL. Abstract 284.





Efficacy

- Median follow-up duration was 5 months (range, 0.1–17 months) as of September 1, 2016
- Median duration of response for the total population was not reached (95% confidence interval [CI], 9 months to not reached)
 - Median duration of response for patients enrolled ≥4 months before data cutoff was not reached (95% CI, 9 months to not reached)
- 83% of all responses were ongoing at the data cutoff (median followup, 5 months [range, 0.1–17 months])
- Median PFS was 2 months (range, 2–3 months)
- 6-month and 12-month PFS rates were 30% and 19%, respectively
- OS rate was 67% at 6 months

1. Balar A et al. Presented at: 2017 Genitourinary Cancers Symposium; Feb 16-18, 2017; Orlando, FL. Abstract 284.







Conclusions

- First-line pembrolizumab demonstrated clinically meaningful antitumor activity in cisplatin-ineligible patients with advanced urothelial cancer
 - 24% of all patients and 27% of those enrolled ≥4 months before data cutoff responded to treatment
 - The PD-L1 high cut point was determined to be CPS ≥10%. Higher response rates were observed in patients with a CPS ≥10%; ORR was 48% for those with CPS ≥10% enrolled ≥4 months before data cutoff
 - 37% of all patients were still receiving treatment, and 83% of responses were ongoing as of the data cutoff
 - Longer follow-up will further elucidate the durability of antitumor activity and impact of pembrolizumab on patient survival
- No new safety signals for pembrolizumab were identified
- These results support the KEYNOTE-361 Phase 3 trial (ClinicalTrials.gov, NCT02853305), which is currently recruiting and is designed to evaluate the efficacy and safety of first-line pembrolizumab with or without chemotherapy vs chemotherapy alone in cisplatin-eligible and -ineligible patients with advanced urothelial cancer

1. Balar A et al. Presented at: 2017 Genitourinary Cancers Symposium; Feb 16-18, 2017; Orlando, FL. Abstract 284.







Why did Pembrolizumab Succeed?

MAY 11, 2017 @ 09:52 AM 11,166 @

Has Merck Lucked Into A \$10 Billion Drug?



Matthew Herper, FORBES STAFF Ø

I cover science and medicine, and believe this is biology's century. FULL BIO \checkmark

Merck-and its cancer drug Keytruda-had a great day yesterday.

First, rival drug giant Roche revealed that a clinical trial failed to show its Tecentriq, a drug similar to Keytruda, extended the lives of patients with bladder cancer. Keytruda, by contrast, had added a median 3.1 months to patients' lives in a similar study. Then, late last night, Keytruda was approved as a first choice for most patients with non-small cell lung cancer when used in combination with a chemotherapy regimen that includes Eli Lilly's Alimta.

MSD Oncology





Outline

- Current standard
- Immunotherapy approvals in mBC
- Clinical Trials
- Summary (Come Monday)







Come Monday.....

- We have 5 IO drugs with some data for use in mUC but only one with phase III trial data to support its use (Pembrolizumab)
- Biomarker studies seem to show a relationship but not clear
- Accelerated approval does not guarantee phase 3 trial success
- More IO drugs and combination trials are ongoing
- Cost will play a big role in its usage and access in non reimbursable markets









3RD SINGAPORE SOCIETY OF ONCOLOGY ASM

ONE FARRER HOTEL | SINGAPORE | 7 - 8 JULY 2017

ABSTRACTS SUBMISSION TIMELINECall for Papers1 Feb – 30 May 2017Abstract Submission Deadline30 May 2017Review Period1 – 5 June 2017Announcement of Results7 June 2017Confirmation by abstract authors (thru registration)10 June 2017

Free Registration for Accepted Abstracts!!!





www.bascoasia.com



THANK YOU



National Cancer Centre Singapore

SingHealth

Ravindran.Kanevaran@singhealth.com.sg



Members of the SingHealth Group Changi General Hospital • KK Women's and Children's Hospital • Singapore General Hospital National Cancer Centre Singapore • National Dental Centre Singapore • National Heart Centre Singapore • National Neuroscience Institute • Singapore National Eye Centre SingHealth Polyclinics